Cancer cover is the clause worth reading first

What follows is an argument about cancer cover in health policies, and about where the received version of it stops being true.

Three common shapes of cancer benefit

Full cancer cover funds diagnosis, treatment and follow-up without a separate cap, subject to the usual policy limits. Time-limited cover funds treatment for a stated period, often measured in years from diagnosis, then stops. Restricted cover funds only treatments recognised or approved by a national assessment body in your country.

These behave identically until the moment they do not, and the difference arrives during treatment.

Drug formularies decide a lot

Insurers maintain lists of funded drugs, and newer or unlicensed-indication treatments may not appear on them. Some policies fund drugs not routinely available in the public system, which is a genuine and specific benefit worth identifying.

In practice, others explicitly mirror public availability, which removes that advantage entirely. Asking whether the policy funds treatments beyond the national approval list is a direct question with a direct answer.

Where the chronic exclusion reappears

Active treatment is acute, and long-term hormonal therapy or surveillance can be reclassified as ongoing management. Some wordings explicitly protect follow-up scans and consultations for a stated number of years, and some do not. That protection is one of the most valuable clauses in a health policy and is rarely advertised.

Its absence does not make a policy bad, but it should change what you expect from it.

Ancillary benefits vary widely

Reconstructive surgery, prostheses, wigs, home nursing, palliative care and travel to treatment are all sometimes covered and sometimes not. These are individually modest and collectively significant during a long treatment course. They appear in a schedule of additional benefits rather than in the main table.

Comparing that schedule across quotes is more informative than comparing headline limits.

Second opinions and trials

Many policies fund a second medical opinion, which is genuinely useful and frequently unused. Clinical trial participation is usually excluded from funding since the trial itself covers the treatment, but associated costs may not be. Where a policy has a designated cancer support nurse or care coordinator, that service is often the most practically valuable element.

In practice, these features are worth asking about explicitly at the quote stage.

Some of this will suit you and some will not, and that is the point.

Read it before you need it

Nobody compares oncology clauses while well, and everybody wishes they had while ill. The four questions are: is the benefit capped, is it time-limited, does it fund drugs beyond national approval, and does it cover follow-up. Those answers describe most of what the policy will do in the situation people buy it for.

In practice, anything specific to a diagnosis or a treatment plan is a matter for your clinicians and, on the policy side, for the insurer in writing.

The takeaway

Ask four questions about the cancer clause before comparing anything else in a health quote.

Pick the one that costs you least, and let the rest wait.